treatment of diseases
treatment of Eosinophilic Esophagitis
revolutionary new treatment
targeted topical treatment
duration of treatment response
people’s health
new candidate compounds
drug discovery company
disease progression
novel drug candidate
inflammatory disease
sustainable health systems
esophagus
health-promotion programmes
theEoE
modulating cell polarity
cell polarity modulation
lower risk of health complications thanks
persistent symptoms
clinical symptoms
Thelial’s patented discovery platform theLiTETM
Thelial’s innovation project
patients’ reduced wellbeing
line targeted therapy
reduced integrity of epithelial cellular barriers
proprietary fly embryo-based technology
significant unmet medical need Thelial Technologies
innovative solution
fewer side-effects
bioavailability
IP
swallowing
high difficulty
better management
nausea
efficacy
pain
eosinophils
revenue
approved product
Europe2020 challenges
tissue remodeling
manufacturing decision points
healthier EU
type of white blood cells
regurgitation
toxicology
key
payers
series of indications
foods
physicians
pathologies
local injury
development
time
environmental allergens
specific cure
features
inflammation
vomiting